CONTRATOS RIO HORTEGA

Datos básicos

Protocolo:
CM15/00246
EUDRACT:
NCT:
Centro:
Año de incio:
Año de finalización:
2018
RRHH NACIONAL F.COMPETITIVA FIN. PUBLICA 53.732,00 €

Documentos

  • No hay documentos

Participantes

Grupos y Plataformas de I+D+i

Financiadores - Promotores

INSTITUTO SALUD CARLOS III

Resultados del Ensayo Clínico


Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes

Ragulan, C; (...); Sadanandam, A

Article. 10.1038/s41598-019-43492-0. 2019


Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.

Henriksen, Tenna Vesterman; (...); Andersen, Claus Lindbjerg

Article. 10.1158/1078-0432.CCR-21-2404. 2022


Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.

Tarazona, Noelia; (...); Cervantes, Andres

Article. 10.1136/esmoopen-2020-000847. 2020


Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen.

Martinez-Ciarpaglini, Carolina; (...); Cervantes, Andres

Article. 10.1111/his.13900. 2019


In the literature: October 2019

Editorial Material. 10.1136/esmoopen-2019-000613. 2019

  • Open Access.

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression

Martinez-Ciarpaglini, C; (...); Cervantes, A

Article. 10.1038/s41379-018-0124-5. 2019


NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer.

Gambardella, V; (...); Cervantes, A

Article. 10.1158/1078-0432.CCR-18-2421. 2019


Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress.

Gambardella, Valentina; (...); Cervantes, Andres

Article. 10.3390/jcm9093049. 2020


Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

Tarazona, N; (...); Cervantes, A

Article. 10.1093/annonc/mdz390. 2019

  • Open Access.

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma.

Gambardella, V; (...); Cervantes, A

Review. 10.1093/annonc/mdz143. 2019


Compartir